SCHEMBL733469

SCHEMBL733469

COC(=O)c1cc(-c2ccccc2)nc(-c2nnn[nH]2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.48
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
ALDH1A1 P00352 8/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GLA P06280 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 3/20 0.42
HSD17B10 Q99714 1/20 0.42
PLA2G2A P14555 1/20 0.42
ALDH1A3 P47895 2/20 0.41
TSHR P16473 1/20 0.41
CTRC Q99895 1/20 0.40
TNKS O95271 1/20 0.39
ADORA1 P30542 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730756 0.85 CTRC (0.55) GAAALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL28490522 0.84 TSHR (0.57) GAAGABRG2GABRB3GABRA5GABRA3
SCHEMBL733150 0.82 GABRG2 (0.44) GAAGABRG2GABRB3GABRA5GABRA3
SCHEMBL741202 0.80 GAA (0.50) GAAGABRG2GABRB3GABRA5GABRA3
SCHEMBL1505455 0.78 GABRG2 (0.50) GABRG2GABRB3GABRA5GABRA3ALDH1A1
SCHEMBL18320581 0.77 MEN1 (0.57) GAAALDH1A1HPGDGLAKDM4E
SCHEMBL28496947 0.76 ALDH1A1 (0.52) GAAGABRG2GABRB3GABRA5GABRA3
SCHEMBL2512905 0.75 KDM4E (0.48) GAAALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL732748 0.74 KDM4E (0.51) GAAGABRG2GABRB3GABRA5GABRA3
SCHEMBL28493223 0.74 ALDH1A1 (0.70) GAAGABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 GAA 3801/4885GABRG2 4088/4885GABRB3 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.